Plain-English translation of NCT04510597 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether removing the affected kidney alongside immunotherapy medications helps people with advanced kidney cancer live longer. You will first receive one of three standard immunotherapy drug combinations (nivolumab and ipilimumab, pembrolizumab and axitinib, or avelumab and axitinib) for about 12 weeks. After that, you'll be randomly assigned to either continue the medication alone or have surgery to remove your kidney and continue the medication.
Doctors are unsure whether removing the kidney in addition to immunotherapy helps patients survive longer with advanced kidney cancer. This trial will provide a clear answer to guide future treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will start with 12 weeks of immunotherapy medication given by IV infusion or taken by mouth, depending on which drug combination you receive. After 12 weeks, you'll have imaging scans to see how the cancer is responding. Then you'll be randomly assigned to either continue your medication alone or have kidney removal surgery (performed within 8 weeks) while continuing the same medication. You'll have follow-up visits and scans to monitor your health and cancer throughout the study.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States